220 related articles for article (PubMed ID: 32650830)
21. Case Report and Literature Review: Primary Pulmonary NUT-Midline Carcinoma.
Zhang Y; Han K; Dong X; Hou Q; Li T; Li L; Zhou G; Liu X; Zhao G; Li W
Front Oncol; 2021; 11():700781. PubMed ID: 34527578
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
[TBL] [Abstract][Full Text] [Related]
23. [A Case Report of Primary Pulmonary NUT Carcinoma and Literature Review].
Liu X; Li Y; Yu M; Zhou L
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):63-68. PubMed ID: 33478193
[TBL] [Abstract][Full Text] [Related]
24. Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.
Lee JK; Louzada S; An Y; Kim SY; Kim S; Youk J; Park S; Koo SH; Keam B; Jeon YK; Ku JL; Yang F; Kim TM; Ju YS
Ann Oncol; 2017 Apr; 28(4):890-897. PubMed ID: 28203693
[TBL] [Abstract][Full Text] [Related]
25. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.
Chau NG; Hurwitz S; Mitchell CM; Aserlind A; Grunfeld N; Kaplan L; Hsi P; Bauer DE; Lathan CS; Rodriguez-Galindo C; Tishler RB; Haddad RI; Sallan SE; Bradner JE; French CA
Cancer; 2016 Dec; 122(23):3632-3640. PubMed ID: 27509377
[TBL] [Abstract][Full Text] [Related]
26. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report.
Jiang J; Ren Y; Xu C; Lin X
Diagn Pathol; 2022 Jan; 17(1):4. PubMed ID: 34996489
[TBL] [Abstract][Full Text] [Related]
27. NUT midline carcinoma of the head and neck: current perspectives.
Napolitano M; Venturelli M; Molinaro E; Toss A
Onco Targets Ther; 2019; 12():3235-3244. PubMed ID: 31118674
[No Abstract] [Full Text] [Related]
28. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
29. Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.
Giridhar P; Mallick S; Kashyap L; Rath GK
Eur Arch Otorhinolaryngol; 2018 Mar; 275(3):815-821. PubMed ID: 29356890
[TBL] [Abstract][Full Text] [Related]
30. NUT midline carcinoma mimicking a germ cell tumor: a case report.
Harada Y; Koyama T; Takeuchi K; Shoji K; Hoshi K; Oyama Y
BMC Cancer; 2016 Nov; 16(1):895. PubMed ID: 27855672
[TBL] [Abstract][Full Text] [Related]
31. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
Chae YK; Viveiros P; Lopes G; Sukhadia B; Sheikh MM; Saravia D; Florou V; Sokol ES; Frampton GM; Chalmers ZR; Ali SM; Ross JS; Chang S; Wang S; Chiec L; Rahbari A; Mohindra N; Villaflor V; Shin SH; Oh M; Anker J; Park LC; Wang V; Chuang J; Park W
J Thorac Oncol; 2019 Oct; 14(10):1807-1817. PubMed ID: 31238177
[TBL] [Abstract][Full Text] [Related]
33. Nuclear protein of the testis midline carcinoma in the oral cavity: retrospective review of those initially diagnosed as poorly differentiated squamous cell carcinoma using an anti-C52B1 antibody.
Aizawa H; Yamada S; Sakai H; Otakiri H; Akita D; Gibo T; Kurita H
Int J Oral Maxillofac Surg; 2019 Oct; 48(10):1265-1272. PubMed ID: 30876795
[TBL] [Abstract][Full Text] [Related]
34. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Ruiz-Patiño A; Arrieta O; Cardona AF; Martín C; Raez LE; Zatarain-Barrón ZL; Barrón F; Ricaurte L; Bravo-Garzón MA; Mas L; Corrales L; Rojas L; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Rizzo M; Ruiz R; Rolfo C; Archila P; Rodríguez J; Sotelo C; Vargas C; Carranza H; Otero J; Pino LE; Ortíz C; Laguado P; Rosell R;
Thorac Cancer; 2020 Feb; 11(2):353-361. PubMed ID: 31828967
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological significance of NUT rearrangements in poorly differentiated malignant tumors of the upper respiratory tract.
Fang W; French CA; Cameron MJ; Han Y; Liu H
Int J Surg Pathol; 2013 Apr; 21(2):102-10. PubMed ID: 22777717
[TBL] [Abstract][Full Text] [Related]
37. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.
Suzuki S; Kurabe N; Ohnishi I; Yasuda K; Aoshima Y; Naito M; Tanioka F; Sugimura H
Pathol Res Pract; 2015 May; 211(5):404-8. PubMed ID: 25466466
[TBL] [Abstract][Full Text] [Related]
38. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
Kloker LD; Sidiras M; Flaadt T; Brecht IB; Deinzer CKW; Groß T; Benzler K; Zender L; Lauer UM
Lung Cancer; 2024 Mar; 189():107496. PubMed ID: 38301600
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
